{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:09:21Z","timestamp":1777464561201,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bladder Cancer"],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>While a definitive cure can be achieved by radical cystectomy and pelvic lymph node dissection in select patients with regional lymphadenopathy, the benefit remains uncertain in patients who present with non-regional metastases. We analyzed the survival outcomes of post-chemotherapy retroperitoneal lymph node dissection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We reviewed our institutional database and identified 13 patients with radiographically evident or biopsy proven retroperitoneal nodal metastases with a significant response to chemotherapy. These patients underwent consolidative surgery with concomitant or delayed retroperitoneal lymph node dissection. The primary endpoints were progression-free survival and disease-specific survival from the time of retroperitoneal lymph node dissection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All patients had primary urothelial cell carcinoma. Twelve patients underwent concomitant radical cystectomy, pelvic and retroperitoneal lymph node dissection. Seven patients (54%) had residual disease in the retroperitoneum and the median number of retroperitoneal nodes containing metastases was 4 (IQR 2\u20136). Six (86%) developed disease recurrences within 2 years of surgery and 5 (71%) died of cancer. Of the 6 patients without residual disease in the retroperitoneum, 2 (33%) developed recurrences and died of disease progression. The 2-year disease-specific survival was worse for patients with residual disease in the retroperitoneum than those without residual retroperitoneal disease (34%, 95% CI 5\u201368 vs 50%, 95% CI 6\u201385).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The presence of retroperitoneal nodal metastases at post-chemotherapy retroperitoneal lymph node dissection is a poor prognosticator. Consolidative surgery with retroperitoneal lymph node dissection provides important prognostic information and may be therapeutic in a very small subset of these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/blc-180186","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T10:46:31Z","timestamp":1542969991000},"page":"13-19","source":"Crossref","is-referenced-by-count":8,"title":["The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum"],"prefix":"10.1177","volume":"5","author":[{"given":"Nick W.","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie S.","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Division, University of Missouri School of Medicine, Columbia, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Machele","family":"Donat","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry W.","family":"Herr","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard H.","family":"Bochner","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2638"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3173"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.052"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.11.039"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00867-0"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35025-5"},{"key":"ref008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2546"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66533-0"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.148"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000067601.29966.4a"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.07.001"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.06.003"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.11.004"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.12.011"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1704290"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9360-5"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.4503"}],"container-title":["Bladder Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-180186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/BLC-180186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/BLC-180186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:23:38Z","timestamp":1777382618000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/BLC-180186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,31]]}},"alternative-id":["10.3233\/BLC-180186"],"URL":"https:\/\/doi.org\/10.3233\/blc-180186","relation":{},"ISSN":["2352-3727","2352-3735"],"issn-type":[{"value":"2352-3727","type":"print"},{"value":"2352-3735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]}}}